Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Oculis Holding AGNASDAQ: OCS

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of CHF 8M rose 62.5% year over year, ahead of the +39.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +54.0% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of CHF 5.5M (-77.7%) for the fiscal year ending Dec 2026, a slowdown from the +12.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 8M+4.0% QoQ
Last fiscal yearDec 2025
CHF 24.63M+12.9% YoY
LTMMar 2026
CHF 27.55M+39.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+62.5%-77.0%-139.5 pp
1 year+12.9%-77.7%-90.6 pp
3-year CAGR+54.0%+70.0%+16.0 pp
5-year CAGR+141.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

CHF · from the income statement

Latest · FY2025
24.63M CHF
Year-over-year change
+12.9%
4-year CAGR
+56.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.2% is the highest of 5, against a peer median of -0.0%.
  • Selling, general & admin amounts to 5466.6% of revenue for OCS, versus a peer median of 467.7%.
OCS Competitors
Selling, General & Admin for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCULOcular Therapeutix, Inc.LTM Mar 2026$124.38M USD+14.7%+17.9%239.0%
HROWHarrow Health, Inc.LTM Mar 2026$86.54M USD——32.2%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$53.04M USD+1.3%-5.0%696.5%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$38.12M USD-1.4%+24.4%11443.7%
OCSOculis Holding AGLTM Mar 2026CHF 27.55M CHF+39.2%+54.0%5466.6%
OKYOOKYO Pharma LimitedFY2025$4.93M USD-33.8%+0.0%—
Peer median (excluding OCS) —-0.0%+9.0%467.7%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.